AI for Science Freemium

Convexia

AI agents for discovering and evaluating overlooked drug assets

Visit official website
PricingFreemium
Starting price$199/mo
Free planUnknown
Free trialYes
APIUnknown
Open sourceNo
DeploymentCloud
Last verifiedJuly 30, 2026
Overview

Tool overview

Convexia is listed under AI for Science AI tools.

Summary

What is Convexia?

Convexia uses specialized AI agents and human scientific review to find, evaluate, and prioritize overlooked drug assets. Its stack covers sourcing, in-silico modeling, commercial analysis, operational risk, probability of success, and licensing-oriented diligence.

Best fit

Best for

Biotech, pharma, and investment teams screening overlooked drug assets

Audience

Who is it for?

Biotechnology teamsPharma business development teamsDrug discovery scientistsLife-science investorsTranslational research teams
Recommendation

Decision note

Reviewed Convexia’s official website, portal, FAQ, Y Combinator profile, and official LinkedIn profile. Confirmed agent-based sourcing, 50-plus evaluation models, scientific and commercial diligence, operational risk simulation, human review, free testing, $199 monthly entry pricing, pilots, and the founders@convexia.bio contact.

Capabilities

Key features

Discovers overlooked preclinical and early-stage drug assets

Runs more than fifty in-silico evaluation models

Assesses binding, ADME, toxicity, and immunogenicity

Scores markets, competition, IP, and reimbursement signals

Models operational risks across CRO, CMC, and trial readiness

Combines specialized agents with expert human review

Workflows

Use cases

Source early-stage drug and repurposing opportunities

Perform scientific and commercial asset diligence

Rank assets for licensing or acquisition

Screen development and trial execution risks

Support go or no-go portfolio decisions

Strengths

Pros

  • Combines sourcing, science, commercial, and operational analysis
  • Uses modular agents instead of one general model
  • Includes repeated human expert review
  • Offers a public entry point for trying agents
Considerations

Cons

  • Model outputs still require scientific validation
  • Full platform and pilot terms are not fully public
  • Computational diligence cannot replace wet-lab and clinical evidence
Considerations

Limitations

Convexia’s assessments are decision-support outputs, not clinical proof or regulatory approval. Teams should validate source data, model performance, assay assumptions, expert methodology, IP status, reproducibility, CRO and trial constraints, licensing rights, and pricing before relying on recommendations.

Cost

Pricing details

Pricing modelFreemium
Starting price$199/mo
Free planUnknown
Free trialYes
Pricing context

Billing options

Monthly subscriptionModule licensingCustom pilot engagements
Pricing context

Pricing note

Convexia states that users can test the agents free without a credit card and lists a $199 per month starting point for the Asset Discovery Agent. Other modules, platform licensing, pilots, and pharma or investment engagements require direct commercial discussion.

View official pricing
Compatibility

Supported languages

  • English
Specs

Technical details

PlatformsWeb
Multilingual supportUnknown
Login requiredYes
Open sourceNo
LicenseProprietary
DeploymentCloud
CompanyConvexia
Launch year2025
Models / versionsAsset Discovery Agent Scientific Evaluation Stack Market Insight Agent Operational Risk Agent Probability of Success Model
Editions / plansFree, Basic, Professional, Organization, and Custom plans
Data confidenceHigh
Last verifiedJuly 30, 2026
Documentation → Data source →
Decision hub

Finish your evaluation of Convexia

Move between similar tools, comparison cards, quick answers, user reviews, and open discussion without leaving the page.

Tools, comparisons & answers

Explore the best next step before choosing Convexia

Browse similar tools, open focused comparison cards, and answer the most common buying questions.

Similar tools Comparisons FAQ
Compare

Compare alternatives

See how Convexia compares with the closest relevant AI tools.

Build custom comparison
Smart AI comparison Convexia vs Elicit Compare pricing, ratings, features, AI score, and use cases. freemium alternative View comparison Smart AI comparison Convexia vs Iris.ai Compare pricing, ratings, features, AI score, and use cases. Paid alternative View comparison Smart AI comparison Convexia vs Dimensions Compare pricing, ratings, features, AI score, and use cases. paid alternative View comparison Smart AI comparison Convexia vs AbInitio Bio Compare pricing, ratings, features, AI score, and use cases. Enterprise only alternative View comparison
Answers

Frequently asked questions

Convexia uses specialized AI agents and human scientific review to find, evaluate, and prioritize overlooked drug assets. Its stack covers sourcing, in-silico modeling, commercial analysis, operational risk, probability of success, and licensing-oriented diligence.
Biotech, pharma, and investment teams screening overlooked drug assets
The listed pricing model for Convexia is Freemium. Pricing can change, so users should verify the latest plan details on the official website.
Yes. The current profile indicates that a free trial is available.
Community proof

User reviews

Real user feedback helps others understand strengths, limitations, and the best-fit workflows before choosing this tool.

No reviews Average rating
0 Total reviews
No reviews yet

Be the first to review Convexia

Share what worked, what did not, who this AI tool is best for, and what buyers should verify before choosing it.

Ask in discussion
Tool discussion

Ask or discuss this tool

Ask questions, share workflows, or discuss your experience with this AI tool.

ReplyContinue threads
EditUpdate your posts
ReportKeep it useful
0Total messages
0Threads
0Replies
Start a useful threadAsk, compare workflows, or reply to reviews

Keep it specific and helpful. You can edit or delete your own messages after posting.

Please log in to join the discussion.

Live discussion

Community messages

Reply to messages and keep the discussion useful. Use Report for abuse or spam. Your own posts can be edited or deleted.

No discussion yetBe the first to ask a question or share a useful workflow.